An observational study in Erectile Dysfunction and Premature Ejaculation, sponsored by Jagiellonian University. Completed at 1 site in Poland. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-18.
Sponsored by Jagiellonian University · Observational
The first large population-based study to evaluate erectile dysfunction (ED) and premature ejaculation (PE) in Poland. The study objective is to assess the prevalence and bother of ED and PE in the representative group of male population of Poland.
701 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
This study's enrollment of 3,000 is above the median of 130 across 125 observational studies indexed under Erectile Dysfunction.
Browse Erectile Dysfunction studies →Jagiellonian University is the lead sponsor of 161 studies on the registry; 35 are open to participants now.
Counted across the registry records on this site, refreshed daily.
A representative group of male Polish population (n=3000).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will be asked to complete validated questionnaires (the five-item International Index of Erectile Function - IIEF-5, Premature Ejaculation Diagnostic Tool - PEDT, International Prostate Symptom Score - IPSS, Overactive Bladder - Validated 8-question Screener - OAB-V8, Hospital Anxiety and Depression Scale - HADS, Athens Insomnia Scale - AIS).
Prevalence of ED in Poland
The prevalence of ED will be assessed using the five-item International Index of Erectile Function (IIEF-5; the lowest score 5; the highest score 25; the lower the score, the greater the severity of the symptoms)
Time frame: Through study completion, an average of 3 months
Prevalence of PE in Poland
The prevalence of PE will be assessed using the Premature Ejaculation Diagnostic Tool (PEDT; the lowest score 0; the highest score 20; the lower the score, the lower the severity of the symptoms)
Time frame: Through study completion, an average of 3 months
Bother of ED and PE in Poland
The degree of associated bother will be assessed using Likert scale (Likert scale: delighted \[score 0\], pleased \[score 1\], mostly satisfied \[score 2\], mixed \[score 3\], mostly dissatisfied \[score 4\], unhappy \[score 5\], or terrible \[score 6\]).
Time frame: Through study completion, an average of 3 months
Prevalence of lower urinary tract symptoms in patients with PE and ED in Poland
The prevalence of lower urinary tract symptoms will be assessed with the International Prostate Symptom Score (IPSS; the lowest score 0, the highest score 35, the lower the score, the lower the severity of the symptoms)
Time frame: Through study completion, an average of 3 months
Prevalence of overactive bladder in patients with PE and ED in Poland
The prevalence of overactive bladder will be assessed with the Overactive Bladder - Validated 8-question Screener (OAB-V8; the lowest score 0; the highest score 40; the lower the score, the lower the severity of the symptoms)
Time frame: Through study completion, an average of 3 months
Prevalence of depressive symptoms in patients with PE and ED in Poland
The prevalence of depressive symptoms will be assessed with the Hospital Anxiety and Depression Scale (HADS; the lowest score 0; the highest score 48; the lower the score, the lower the severity of the symptoms)
Time frame: Through study completion, an average of 3 months
Prevalence of insomnia in patients with PE and ED in Poland
The prevalence of insomnia will be assessed with the Athens Insomnia Scale (AIS; the lowest score 0; the highest score 24; the lower the score, the lower the severity of the symptoms)
Time frame: Through study completion, an average of 3 months
Ran from Jul 2022 to primary completion in Nov 2022, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.